Yoshida K, Hosoya Y, Sumi S, Honda M, Moriguchi H, Yano M, Ueda Y
Department of Urology, Dokkyo University School of Medicine, Tochigi, Japan.
Oncology. 1997 May-Jun;54(3):220-5. doi: 10.1159/000227692.
We evaluated the expression of epidermal growth factor receptor (EGFR) in 21 patients with renal cell carcinoma (RCC) by immunohistochemical staining of frozen tumor sections using a monoclonal antibody for EGFR and by a ligand binding method using radiolabeled epidermal growth factor. EGFR was detected in 16 of the 21 cases by ligand binding, while 11 of the 21 cases were detected by immunohistochemical staining. A significant correlation was observed between the two methods in detecting EGFR (p < 0.0001). EGFR was detected by the ligand binding method in all patients who died of RCC. Four cases that were graded as EGFR-negative on immunohistochemistry died of RCC. Observations suggest the ligand binding method was more sensitive than the immunohistochemical method in detecting EGFR and forecasting patient survival.
我们通过使用针对表皮生长因子受体（EGFR）的单克隆抗体对冷冻肿瘤切片进行免疫组织化学染色，以及使用放射性标记的表皮生长因子的配体结合方法，评估了21例肾细胞癌（RCC）患者中EGFR的表达情况。通过配体结合法在21例病例中的16例检测到了EGFR，而通过免疫组织化学染色在21例病例中的11例检测到了EGFR。在检测EGFR时，两种方法之间观察到显著相关性（p < 0.0001）。通过配体结合法在所有死于RCC的患者中均检测到了EGFR。免疫组织化学分级为EGFR阴性的4例患者死于RCC。观察结果表明，在检测EGFR和预测患者生存方面，配体结合法比免疫组织化学方法更敏感。
